2022
DOI: 10.1016/j.rvsc.2022.06.020
|View full text |Cite
|
Sign up to set email alerts
|

Assessment of selegiline and trilostane combined therapy efficacy for canine pituitary-dependent hypercortisolism treatment: A pilot randomized clinical trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(1 citation statement)
references
References 49 publications
0
1
0
Order By: Relevance
“…Due to different efficacy, it was withdrawn for human use in the United States in the 1990s. However, it was approved for treating Cushing’s syndrome in pets such as dogs and cats 11 , 12 . The identified potent h 3β-HSD2 and r 3β-HSD1 inhibitors of curcumin analogues such as DMC and BDMC may be potential food additives for therapeutic purposes and further preclinical studies are needed.…”
Section: Discussionmentioning
confidence: 99%
“…Due to different efficacy, it was withdrawn for human use in the United States in the 1990s. However, it was approved for treating Cushing’s syndrome in pets such as dogs and cats 11 , 12 . The identified potent h 3β-HSD2 and r 3β-HSD1 inhibitors of curcumin analogues such as DMC and BDMC may be potential food additives for therapeutic purposes and further preclinical studies are needed.…”
Section: Discussionmentioning
confidence: 99%